An article aimed at finding new strategies to prevent GBM tumor cells infiltration
February 6, 2020
MEDPNC’s Chief Scientists, Dr. Nataly Kravchenko – Balasha yesterday published, toghether with her colleagues from the Hebrew University, an article aimed at finding new strategies to prevent GBM tumor cells infiltration.
Read More
Improdia signed a cooperation agreement with Sourasky Medical Center
December 18, 2019
The Israeli diagnostics company, Improdia, has signed a cooperation agreement with Tel Aviv Sourasky Medical Center (Ichilov) to perform a large-scale clinical trial on diabetes patients aimed at preventing lethal complications based on their immune status. preventing lethal complications based on their immune status.
Read More
Diagyn and MEDPNC participated in WHII Congress
July 16, 2019
Diagyn and MEDPNC, along with other leading and innovative Israeli companies, took part in the 1st World Congress on Women’s Health Innovations and Inventions that was held at The Tel Aviv Hilton Hotel July 10-11, 2019, addressing specific unmet needs in women’s health.
The event was covered by journalists from Israel and from around the world.
Read More
Prof. Raphael D. Levine has joined MEDPNC’s Advisory Board
May 20, 2019
Raphael D. Levine is the Max Born Professor of Natural Philosophy at the Hebrew University of Jerusalem. He is a theorist, and one of the pioneers and a leader of worldwide recognition in the modern theory of chemically reactive collisions and unimolecular reactions.
Read More
Diagyn will participate in the MIXiii-Biomed Conference
May 16, 2019
Diagyn is taking part in the 18th National Life Science & Techology week, to be held on 14-16th May 2019
Read More
A new Improdias` patent was granted in Israel
May 13, 2019
A Novel Biomarker SNX9 For Chronic Inflammation and Associated Immunosuppression and a new regulator of T-Cell Expression and receptor expression and function
Read More